The Traderszone Network

Published in TZ Latest News 15 November, 2017 by The TZ Newswire Staff

Arsanis Announces Pricing of Initial Public Offering

WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) — Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses.

read more